Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US6402683063
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000BHCYJ1
NKTR

Nektar Therapeutics
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Nektar Therapeutics
ISIN
US6402683063
TICKER
NKTR
MIC
XNAS
REUTERS
NKTR.OQ
BLOOMBERG
NKTR US
Sun, 26.04.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - April 26, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Sat, 25.04.2026       Nektar Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Fri, 24.04.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - April 24, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Fri, 24.04.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - April 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you p...
Thu, 23.04.2026       Nektar Therapeutics

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system...
Thu, 23.04.2026       Nektar Therapeutics

SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced the closing of its underwritten public offering of $373.8 million of shares of its common stock. Nektar sold 4,062,500 shares of common stock in the offering,...
Thu, 23.04.2026       Nektar Therapeutics

LOS ANGELES, April 23, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) have opportunity to lead the securities fraud class action lawsuit....
Thu, 23.04.2026       Nektar Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Thu, 23.04.2026       Nektar Therapeutics

The Red Flags: What Insiders Allegedly Knew Before Shareholders DidNEW YORK, April 23, 2026 /PRNewswire/ -- SueWallSt announces that a securities class action has been filed against Nektar Therapeutics (NASDAQ: NKTR). YOU MAY BE AFFEC...
Thu, 23.04.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - April 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purcha...
Silent Ad
Wed, 22.04.2026       Nektar Therapeutics

Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRANEW YORK, April 22, 2026 /PRNewswire/ -- IMPORTANT DATE: May 5, 2026. Investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025 and wish to seek appointment as lead plaintiff must file a motion by this date. Start your...
Wed, 22.04.2026       Nektar Therapeutics

NEW YORK, April 22, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclus...
Wed, 22.04.2026       Nektar Therapeutics

SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten public offering of $325 million of shares of its common stock. Nektar is selling 3,532,609...
Tue, 21.04.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - April 21, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Tue, 21.04.2026       Nektar Therapeutics

Bernstein Liebhard LLP:Do you, or did you, own shares of Nektar Therapeutics (NASDAQ: NKTR)?Did you purchase your shares between February 26, 2025 and December 15, 2025, inclusive?Did you lose money in your investment in Nektar Therapeutics?Do you want to discuss your rights?New York, New York--(Newsfile Corp. - April 21, 2026) - Bernstein Liebhard...
Tue, 21.04.2026       Nektar Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Tue, 21.04.2026       Nektar Therapeutics

NEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR during the class period listed are encouraged to...
Tue, 21.04.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - April 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you p...
Mon, 20.04.2026       Nektar Therapeutics

SAN FRANCISCO, April 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten public offering of $250,000,000 of its shares of its common stock and, in lieu of common sto...
Mon, 20.04.2026       Nektar Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Silent Ad
Mon, 20.04.2026       Nektar Therapeutics

29% and 31% of patients in the 18 µg/kg and 24 µg/kg extension arms, respectively, achieved new SALT Score ≤20 from week 36 to week 52 with continued twice-monthly treatmentIncreasing proportions of patients achieved clinically meaningful hair growth thresholds across numerous SALT measurements with 94% of patients completing treatment extensionFa...
Mon, 20.04.2026       Nektar Therapeutics

Instrument ID [24281011] (ITH0 - US6402683063) suspended...
Mon, 20.04.2026       Nektar Therapeutics

LOS ANGELES, April 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholder...
Mon, 20.04.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - April 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purcha...
Sun, 19.04.2026       Nektar Therapeutics

SAN FRANCISCO, April 19, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review 52-week topline results from the 16-week extension treatment period of the ongoing Phase 2b REZOLVE-A...
Sun, 19.04.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - April 19, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Sat, 18.04.2026       Nektar Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Fri, 17.04.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - April 17, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Thu, 16.04.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - April 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you p...
Thu, 16.04.2026       Nektar Therapeutics

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers.  The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv- 01951, is on behalf...
Thu, 16.04.2026       Nektar Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Thu, 16.04.2026       Nektar Therapeutics

Key Dates and Disclosure Events Shareholders Need to KnowNEW YORK, April 16, 2026 /PRNewswire/ -- SueWallSt encourages investors who suffered losses in Nektar Therapeutics (NASDAQ: NKTR) to contact the firm. Those who purchased NKTR securities between February 26, 2025 and December 15, 2025 may be entitled to recover damages. Find out if you are e...
Thu, 16.04.2026       Nektar Therapeutics

NEW YORK, April 16, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclu...
Wed, 15.04.2026       Nektar Therapeutics

LOS ANGELES, April 15, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR)....
Wed, 15.04.2026       Nektar Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Wed, 15.04.2026       Nektar Therapeutics

Alert: Claims Focus on Alleged Misrepresentations About REZOLVE-AA Patient Enrollment ComplianceNEW YORK, April 15, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities of a pending securities class action....
Wed, 15.04.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - April 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purcha...
Tue, 14.04.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - April 14, 2026) - Bernstein Liebhard LLP:Do you, or did you, own shares of Nektar Therapeutics (NASDAQ: NKTR)?Did you purchase your shares between February 26, 2025 and December 15, 2025, inclusive?Did you lose money in your investment in Nektar Therapeutics?Do you want to discuss your rights?Bernstein Liebhard...
Tue, 14.04.2026       Nektar Therapeutics

NEW YORK, April 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR during the class period listed are encouraged to...
Mon, 13.04.2026       Nektar Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Mon, 13.04.2026       Nektar Therapeutics

BENSALEM, Pa., April 13, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NEKTAR THERAPEUTICS (NKTR), CONTAC...
Mon, 13.04.2026       Nektar Therapeutics

LOS ANGELES, April 13, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U....
Mon, 13.04.2026       Nektar Therapeutics

LOS ANGELES, April 13, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholder...
Sat, 11.04.2026       Nektar Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Fri, 10.04.2026       Nektar Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Thu, 09.04.2026       Nektar Therapeutics

NEW YORK, April 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline....
Thu, 09.04.2026       Nektar Therapeutics

LOS ANGELES, April 9, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) have opportunity to lead the securities fraud class action lawsuit....
Thu, 09.04.2026       Nektar Therapeutics

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv-01951, is on behalf of...
Wed, 08.04.2026       Nektar Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Tue, 07.04.2026       Nektar Therapeutics

New York, New York--(Newsfile Corp. - April 7, 2026) - Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.Should You Join the Nektar Class Acti...